Showing results (101-110 of 4,635) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|December 13, 2006
Panitumumab the first fully human monoclonal antibody: from the bench to the clinicMichael Cohenuram, Muhammad Wasif Saif
Anti-Cancer Drugs|December 13, 2006
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans-Joachim Stemmler, Manfred Schmitt, Amina Willems, et al.
Anti-Cancer Drugs|December 13, 2006
Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell lineEun Ji Jung, You Mie Lee, Byung Lan Lee, et al.
Anti-Cancer Drugs|December 13, 2006
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsJohn F Deeken, William D Figg, Susan E Bates, et al.
Anti-Cancer Drugs|December 13, 2006
An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activityQing-fang Miao, Xiao-yun Liu, Bo-yang Shang, et al.
Anti-Cancer Drugs|December 13, 2006
Role of p53 in irinotecan-induced intestinal cell death and mucosal damageJoanne M Bowen, Rachel J Gibson, Andrea M Stringer, et al.
Anti-Cancer Drugs|March 14, 2007
Src, chemoresistance and epithelial to mesenchymal transition: are they related?Ami N Shah, Gary E Gallick
Anti-Cancer Drugs|March 14, 2007
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivoTina M Avolio, Yoon Lee, Ningping Feng, et al.
Anti-Cancer Drugs|March 14, 2007
Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I studyUte Rupp, Eva Schoendorf-Holland, Michael Eichbaum, et al.
Anti-Cancer Drugs|September 27, 2006
Cyclopentenone: a special moiety for anticancer drug designMatteo Conti
Pageof 464